Traws Pharma | 10-Q: FY2025 Q3 Revenue: USD 0

LB filings
2025.11.13 12:33
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.34.

EBIT: As of FY2025 Q3, the actual value is USD -4.151 M.

Segment Revenue

  • Revenue: For the three months ended September 30, 2025, Traws Pharma, Inc. reported no revenue, compared to $57,000 for the same period in 2024. For the nine months ended September 30, 2025, revenue was $2,790,000, compared to $170,000 in 2024, primarily due to the recognition of deferred revenue following the termination of a license agreement with Symbio Pharmaceuticals Limited.

Operational Metrics

  • Net Income (Loss): The net loss for the three months ended September 30, 2025, was $3,962,000, compared to a net loss of $8,475,000 for the same period in 2024. For the nine months ended September 30, 2025, net income was $16,613,000, compared to a net loss of $136,601,000 in 2024.
  • Research and Development Expenses: R&D expenses decreased to $2,311,000 for the three months ended September 30, 2025, from $5,113,000 in 2024. For the nine months ended September 30, 2025, R&D expenses were $7,108,000, down from $10,989,000 in 2024.
  • General and Administrative Expenses: These expenses decreased to $1,744,000 for the three months ended September 30, 2025, from $3,480,000 in 2024. For the nine months ended September 30, 2025, the expenses were $6,189,000, compared to $8,813,000 in 2024.

Cash Flow

  • Operating Cash Flow: Net cash used in operating activities was $15,427,000 for the nine months ended September 30, 2025, compared to $25,752,000 in 2024.
  • Investing Cash Flow: Net cash used in investing activities was $2,585,000 for the nine months ended September 30, 2025, compared to $3,648,000 in 2024.
  • Financing Cash Flow: Net cash provided by financing activities was $3,046,000 for the nine months ended September 30, 2025, compared to $13,999,000 in 2024.

Unique Metrics

  • Change in Fair Value of Warrant Liability: For the nine months ended September 30, 2025, there was a change in fair value of warrant liability of $26,656,000.

Future Outlook and Strategy

  • Core Business Focus: Traws Pharma, Inc. is focused on developing tivoxavir marboxil and ratutrelvir, with strategic objectives to establish additional partnerships for narazaciclib and rigosertib. The company is exploring various funding sources to support ongoing clinical trials and operations.
  • Non-Core Business: The company is pursuing strategic partnerships for its oncology assets, including narazaciclib and rigosertib, to further their development.
  • Priority: The company emphasizes the need for additional financing to fund its clinical trials and operations, with plans to explore both dilutive and non-dilutive funding sources.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.